WCA
YMAB

Windsor Creek Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Windsor Creek Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,500
Closed -$65K – 212
2020
Q1 		$65K Buy
+2,500
New +$72.6K 0.02% 160

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Windsor Creek Advisors's YMAB Position: Q2 2020 in Review

Windsor Creek Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q2 2020, closing a stake of 2,500 shares — an estimated $65K sold.

Windsor Creek Advisors first reported a position in YMAB in Q1 2020 and held it in 1 quarter. The position peaked at $65K in Q1 2020. 109 funds tracked by Wall St. Rank hold YMAB as of Q2 2020.

  • Windsor Creek Advisors reported no remaining Y-mAbs Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Windsor Creek Advisors sold 2,500 Y-mAbs Therapeutics shares in Q2 2020, an estimated $65K.
  • Windsor Creek Advisors first reported a position in Y-mAbs Therapeutics in Q1 2020 and held it in 1 quarter.
  • Windsor Creek Advisors's Y-mAbs Therapeutics position peaked at $65K in Q1 2020.
  • 109 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2020.

Based on Windsor Creek Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.